P I M Schmitz
Overview
Explore the profile of P I M Schmitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oosten A, Oldenmenger W, Van Zuylen C, Schmitz P, Bannink M, Lieverse P, et al.
Eur J Cancer
. 2011 Jul;
47(15):2341-6.
PMID: 21798736
Background: Palliative sedation (PS) is necessary in a significant percentage of patients dying on an acute palliative care unit (PCU). Common indications are terminal restlessness, pain and dyspnoea. On our...
2.
van der Ploeg A, van Akkooi A, Schmitz P, van Geel A, de Wilt J, Eggermont A, et al.
Ann Surg Oncol
. 2011 May;
18(12):3300-8.
PMID: 21537867
Background: Management of patients with clinically detectable lymph node metastasis to the groin is by ilioinguinal or combined superficial and deep groin dissection (CGD) according to most literature, but in...
3.
Surmont V, Aerts J, van Klaveren R, Tournoy K, Tan K, Vernhout R, et al.
Oncology
. 2010 Jun;
78(3-4):267-70.
PMID: 20523087
Purpose: Carboplatin area under the curve (AUC) 5 ml/min on day 1 with gemcitabine 1,250 mg/m(2) on day 1 and day 8 is a widely used regimen in advanced non-small...
4.
Strijbos M, Gratama J, Schmitz P, Rao C, Onstenk W, Doyle G, et al.
Eur J Cancer
. 2010 Apr;
46(11):2027-35.
PMID: 20399640
Purpose: We investigated whether serum markers of angiogenesis endothelin-1 (ET-1) and tissue factor (TF), and/or markers of vascular damage such as circulating endothelial cells (CECs), or their relative changes during...
5.
Oosten A, Seynaeve C, Schmitz P, den Bakker M, Verweij J, Sleijfer S
Sarcoma
. 2010 Jan;
2009:348910.
PMID: 20066161
Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal...
6.
Surmont V, Aerts J, Pouw E, Tan K, Vernhout R, Gras J, et al.
Lung Cancer
. 2009 Mar;
66(3):333-7.
PMID: 19327865
Background: Oral treatment regimens with few side effects are appealing in the 2nd or 3rd line treatment of non-small cell lung cancer (NSCLC) patients. Purpose: The aim was to investigate...
7.
van Akkooi A, Bouwhuis M, de Wilt J, Kliffen M, Schmitz P, Eggermont A
Br J Surg
. 2007 Aug;
94(10):1293-9.
PMID: 17702089
Background: Sentinel node (SN) status is the most important prognostic factor for overall survival in stage I or II melanoma. Yet SN-positive tumours with submicroscopic involvement of the SN (clusters...
8.
van Akkooi A, Bouwhuis M, van Geel A, Hoedemaker R, Verhoef C, Grunhagen D, et al.
Eur J Surg Oncol
. 2006 Dec;
33(1):102-8.
PMID: 17161577
Melanoma patients with clinically evident regional lymph node metastases are treated with therapeutic lymph node dissections (TLNDs). The aim of this study was to evaluate morbidity and mortality following TLND...
9.
van Akkooi A, de Wilt J, Verhoef C, Schmitz P, van Geel A, Eggermont A, et al.
Ann Oncol
. 2006 Sep;
17(10):1578-85.
PMID: 16968875
As only about 20% of sentinel node (SN) positive melanoma patients have additional non-SN lymph node involvement in the Completion Lymph Node Dissection (CLND) specimen, we tried to identify a...
10.
Merkies I, Schmitz P
J Neurol Neurosurg Psychiatry
. 2006 Mar;
77(8):970-2.
PMID: 16549419
Objective: To determine which widely used disability measure in Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) shows the strongest association with patients' rating scores. Methods: Five disability scales...